tirzepatide vs semaglutide benefits caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Tirzepatide vs Semaglutide: What's the

The goal is not elimination but smart substitution

doi: 10.1016/j.ejphar.2020.173528 78 BornerTWorkingerJLTinsleyICFortinSMSteinLMChepurnyOGet al

Studies are ongoing to assess cardiovascular parameters, kidney markers, and gastrointestinal side effects over extended periods

To view a copy of this licence, visit About this article Cite this article Valds-Calero, I., Frhbeck, G

Tailored Weight Loss Plans: No two bodies are the same, which is why we customize every aspect of your treatment plan to align with your health goals and lifestyle

May 27, 2026, 09:00 ET Phase 3 REIMAGINE 13 trial results across a range of type 2 diabetes patient groups offer further insight into CagriSema, a novel amylin RA and a GLP-1 RA in a fixed-dose combination 1 Mid-stage trial data for investigational zenagamtide explore the safety and efficacy of the injectable formulation of the novel GLP-1/amylin-based treatment 2 New Ozempic and Wegovy data provide further evidence of semaglutide's strong cardiometabolic profile PLAINSBORO, NJ and BAGSVRD, Denmark, May 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association (ADA), taking place in New Orleans, June 58, 2026